NCT07420790 Design and Validation of a Generative AI and Propensity Score Matching Model for the VEN-DEC Phase II Study in Elderly AML Eligible for Allo-SCT; Evaluation of an Exploratory Approach Respect to a Randomized Phase III Trial
| NCT ID | NCT07420790 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia |
| Condition | Acute Myeloid Leukemia |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,941 participants |
| Start Date | 2026-02-20 |
| Primary Completion | 2026-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,941 participants in total. It began in 2026-02-20 with a primary completion date of 2026-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To better delineate the contribution of VEN-DEC to the treatment of AML patients aged between ≥ 60 and \< 75 years and deemed fit for Allo-HSCT, real-world data on a patient-level basis will be collected and utilized to generate a matched control cohort of same AML patients treated with intensive chemotherapy. In addittion, to further validate the efficacy of the VEN-DEC treatment approach in elderly AML patients, an advanced generative AI model will be constructed and trained using the historical cohort data. The AI model aims to simulate outcomes based on the standard
Eligibility Criteria
Inclusion Criteria: * Patients with AML treated with cht (historical cohort) or VenDec (experimental cohort) Exclusion Criteria: \-
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07420790 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Acute Myeloid Leukemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07420790 currently recruiting?
Yes, NCT07420790 is actively recruiting participants. Contact the research team at domenico.russo@unibs.it for enrollment information.
Where is the NCT07420790 trial being conducted?
This trial is being conducted at Brescia, Italy.
Who is sponsoring the NCT07420790 clinical trial?
NCT07420790 is sponsored by Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia. The trial plans to enroll 1,941 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.